Geneva, Feb. 13 -- International Clinical Trials Registry received information related to the study (NCT07388563) titled 'Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma' on Feb. 4.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: National Cancer Institute (NCI)
Condition:
Lymphoma, T Cell, Peripheral
T-cell Lymphoma
Angioimmunoblastic T-cell Lymphoma
Anaplastic Large Cell Lymphoma
Monomorphic Epitheliotropic Intestinal T-cell Lymphoma
Adult T-cell Leukemia/Lymphoma
Intervention:
Drug: azacitidine
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: ...